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Background: The aim of the present study was to investigate the expression of glucose-related protein 78 (GRP78)
and heparanase (HPA) in oral squamous cell carcinoma (OSCC) and their relationship with clinicopathological
parameters and potential implications for survival.
Methods: A total of 46 patients with OSCC and 10 normal individuals were recruited for the study. GRP78 and HPA
expression were determined in the lesion tissues using immunohistochemical analysis. The correlation between
GRP78 and HPA was assessed using the Spearman correlation analysis. The associations of GRP78 and HPA with
clinicopathological characteristics and survival were examined using the x2-test, Kaplan–Meier, or Cox regression.
Results: Patients with OSCC showed a statistically significant higher prevalence of GRP78 and HPA expression than
normal oral tissues. GRP78 and HPA expression was positively correlated with size, TNM stage, histological grade,
lymphatic metastasis, and distant metastasis in OSCC patients. GRP78 expression was also positively correlated with
HPA expression. Positive GRP78 and HPA expression was inversely correlated with survival in OSCC patients.
Conclusions: HPA expression was found to be positively correlated with GRP78 expression. GRP78 and HPA are
biomarkers that may have the potential to guide the treatment of oral cancer patients.
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PrognosisBackground
OSCC is the sixth most common malignancy in the
world and has a worldwide incidence of over 263,900
new cases annually [1]. Despite numerous advances in
diagnosis and treatment in the last half a century, such
as surgery, chemotherapy, radiation, and other com-
binational therapies, mortality rates have remained un-
changed. The five-year survival rate has remained at
between 40 and 50% [2]. Currently, the treatment of
choice for OSCC is considered by clinicopathological
parameters. However, tumor outcome can differ even
among patients whose tumors have the same clinicopatho-
logical parameters and who undergo the same treatments.
This shows that individualized patient management is* Correspondence: xjch9999@163.com
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reproduction in any medium, provided the orneeded [3]. Tumor progression is a multifactorial, multi-
step process, resulting in a heterogeneous group of cancers.
Better understanding of the characteristics of tumors may
ultimately help us provide patients with more individual-
ized treatment. Recently, molecular-targeted therapy has
drawn attention. This focuses on tumor cell specificity and
the expression of molecules and proteins and their possible
use in targeted therapy [4]. For molecular-targeted therapy
to be effective, new factors for OSCC must be found.
GRP78 is an important member of the heat shock pro-
tein family 70 (HSPs70). It is localized to the endoplas-
mic reticulum (ER). GRP78 has many functions, but it
plays a particularly essential role in protein biosynthesis.
As a chaperone protein, it takes part in assembling, folding,
and transporting newly synthesized proteins [5]. GRP78
also serves as a sensor for ER stress (ERS) under many or-
dinary physiological and pathological conditions, such as in
patients with genetic mutations affecting secretory protein. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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folded or misfolded proteins to accumulate in the lumen of
the ER, resulting in ERS [6,7]. In order to sustain cytosolic
ER homeostasis, cells activate a set of tightly controlled
regulatory programs called the unfolded protein response
(UPR) [6,7]. Some recent reports have demonstrated that
regulation and expression of GRP78 are associated with re-
sistance to apoptosis, and that overexpression of GRP78
may be involved in tumor progression in some forms of
carcinoma [8,9]. However, tumor treatment failure is
mainly attributable to metastasis. HPA is an endo-β-D-glu-
curonidase that specifically cleaves the side chains of hepa-
ran sulfate proteoglycans (HSPGs) [10]. For tumor cells to
accomplish invasion and metastasis, they must first break
through the extracellular matrix (ECM) and basement
membrane (BM), which are mainly made up of HSPGs.
Previous studies have shown that expression of HPA, which
is the only enzyme capable of degrading HSPGs, is corre-
lated to the degree of tumor invasion and metastasis in
some malignancies [11,12]. Although the roles of GRP78
and HPA in the progression and prognosis of various hu-
man tumor tissues are widely recognized, there is a lack of
reports on OSCC. Previous studies have shown that GRP78
is a marker of ERS, and that HPA can regulate the invasion
and metastasis of tumor cells. When the tumor microenvir-
onment becomes hypoxic, acidic, glucose-deprived, or is
subjected to radiation treatment, tumor cells can invade,
metastasize, and induce ERS, triggering UPR in tumor cells.
The relationships among these factors have yet to be ex-
plained. With this in mind, immunohistochemistry was
used to assess GRP78 and HPA expression in paraffin-
embedded primary and metastatic tumor sections from pa-
tients with OSCC. The purpose of the present study was to
investigate the correlations among GRP78, HPA, the clini-
copathological parameters of OSCC, and prognostic signifi-
cance. The results may positively influence the guiding of
treatment for oral cancer patients.
Methods
Patients
In this retrospective study, 10 normal individuals with pre-
cancerous lesions and 46 patients with OSCC were re-
cruited from the Department of Stomatology of the First
Affiliated Hospital of Bengbu Medical College, (People’s
Republic of China) between 2006 and 2008, and for whom
tissue specimens from the local pathology repository and
clinical follow up data were available. None of the patients
had received irradiation or chemotherapy prior to surgery.
All patients gave informed consent for participation
and were interviewed uniformly before surgery by a
well-trained interviewer. The questionnaire used in the
interview addressed details regarding general demog-
raphy, current and past cigarette smoking status, and
alcohol consumption. Patients who had ever smokedcigarettes or drunk alcohol on a regular basis (at least
once a week for one year) were classified as tobacco
and alcohol users, respectively. For each patient, tumor
stage and disease grade were classified by the patholo-
gist according to guidelines published in the seventh
edition of the TNM classification of the International
Union against Cancer (UICC). The study was con-
ducted according to the regulations of the local ethics
committee and the laws of China.
Patient characteristics and clinicopathological features
Demographic data and tumor characteristics are summa-
rized in Table 1. A total of 46 patients were recruited in
this retrospective study: 9 female and 37 male. The age
of the participants ranged from 5 to 75 years (median
60 years), and the median tumor size was 3.1 cm (1 to
5.2 cm). The mean follow up period was 66 months (8 to
82 months). Overall, 84.8% (39 out of 46) of the patients
were cigarette smokers, and 78.3% (36 out of 46) were alco-
hol drinkers. The histological tumor grades were G1-G2 in
12 cases and G3-G4 in 34 cases. Tests were positive for
lymphatic invasion in 19 cases. The tumor stages were
T1-T2 in 31 cases and T3-T4 in 15 cases. Distant metastasis
at presentation (M1) was observed in 11 cases. Pathologic
stages were I-II in 23 cases and III-IV in 23 cases.
Reagents
Goat monoclonal antibodies against human GRP78 and
HPA were purchased from Santa Cruz Biotechnology
(Santa Cruz, California, United States) and Abcam Biotech-
nology (Hong Kong, China). Elivison™ Plus Immunohisto-
chemical Kits and Diaminobenzidine (DAB) Chromogenic
Kits were purchased from Fuzhou Maixin Bio-technology
Co. (Fuzhou, China). Phosphate-buffered saline (PBS,
pH = 7.4) and sodium citrate-hydrochloric acid buf-
fer solution (pH = 6.0) reagents were prepared in the
Department of Pharmacy, Bengbu Medical College,
Bengbu, Anhui, China.
Immunohistochemistry
The expression of GRP78 and HPA was determined using
Elivision™ immunohistochemical methods and DAB
coloration. Briefly, the paraffin-embedded tumor sec-
tions (5 μm) were deparaffinized and dehydrated with
graded alcohol. After washing for 10 minutes in PBS,
the sections were heated for 15 minutes at 95°C in a
sodium citrate-hydrochloric acid buffer solution to re-
pair antigens. The endogenous peroxidase activity was
quenched by incubation of the sections in methanol
containing 3% H2O2 for 10 minutes at room temperature.
After several washes in PBS, the sections were incubated
with anti-GRP78 antibody (sc-13968) or anti-HPA antibody
(ab85543) overnight at 4°C in a humidified chamber. In-
stead of reacting with the primary antibodies, the sections
Table 1 Correlations of GRP78 and HPA expression in oral cancer with the clinicopathological parameters
Variable n % GRP78 P HPA P
Positive Negative Positive Negative
Tissue 0.003 0.033
Normal 10 17.9 0 10 0 10
OSCC 46 82.1 27 19 19 27
Gender 0.358 0.555
Male 37 80.4 20 17 14 23
Female 9 19.6 7 2 5 4
Age 0.606 0.055
≤60 27 58.7 15 12 8 19
>60 19 41.3 12 7 11 8
Tumor size 0.001 0.036
≤3.1 23 50.0 8 15 6 17
>3.1 23 50.0 19 4 13 10
Tumor stage 0.001 0.000
T1-T2 31 67.4 13 18 7 24
T3-T4 15 32.6 14 1 12 3
Lymphatic metastasis 0.000 0.012
N0 27 58.7 10 17 7 20
N1-3 19 41.3 17 2 12 7
Distant metastasis 0.033 0.000
M0 35 76.1 17 18 8 27
M1 11 23.9 10 1 11 0
TNM stage 0.000 0.000
I-II 23 50.0 6 17 3 20
III-IV 23 50.0 21 2 16 7
Histologic grade 0.018 0.016
G1-G2 12 26.1 11 1 9 3
G3-G4 34 73.9 16 18 10 24
Cigarette smoking 0.246 0.180
Yes 39 84.8 21 18 14 25
No 7 15.2 6 1 5 2
Alcohol drinking 0.787 1.000
Yes 36 78.3 22 14 15 21
No 10 21.7 5 5 4 6
P <0.05 was considered to be statistically significant.
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buffer) for 20 minutes at room temperature. After a
thorough wash in PBS, the sections were treated with
the anti-goat antibody (reagent B, DAB substrate) for
30 minutes at room temperature. After being washed
in PBS, they were developed in freshly prepared DAB
solution for 8 minutes and then counterstained with
hematoxylin, dehydrated, air-dried, and mounted onto
slides.Evaluation of slides
The slides were evaluated by two independent observers
using a light microscope in a blinded fashion. Cases of
disagreement were re-evaluated on a double-headed micro-
scope until consensus was reached. Ten visual fields were
randomly selected from each slide. A score of 0 to 3, corre-
sponding to colorless, faint yellow, yellow-brown, and
brown, was given to evaluate the intensity of staining. A
score of 0 to 3 was used to evaluate the relative number of
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the cells were positive were given a score of 0; samples in
which between 10 and 50% of the cells were positive were
given a score of 1; samples in which between 50 and 75% of
the cells were positive were given a score of 2; samples in
which more than 75% of the cells were positive were given
a score of 3. The modified histochemical score was ob-
tained by multiplying the score for the intensity of staining
by the score for the relative number of positive cells. Based
on this final score, results ≤1 were considered negative and
those >1 positive.Statistical analysis
Statistical analysis was performed using the SPSS statistical
package (SPSS, Chicago, Illinois, United States). The associ-
ations between GRP78, HPA expression, and clinicopatho-
logical parameters were evaluated using the x2-test. The
correlation between GRP78 and HPA was assessed by the
Spearman correlation analysis. Survival curves were gener-
ated using the Kaplan-Meier method and compared using
the log-rank test. The Cox proportional hazard model was
used to assess independent factors for the significance of





Figure 1 Immunohistochemistry staining patterns of GRP78 and HPA
OSCC and normal tissues by immunostaining (×400). A-1: GRP78 in normal
A-3: GRP78 in OSCC tissues: positive expression. (B) HPA expression in OSC
tissues: no expression; B-2: HPA in OSCC tissues: negative expression; B-3: H
78; HPA, heparanase; OSCC, oral squamous cell carcinoma.Results
GRP78 and HPA expression in oral squamous cell
carcinoma and normal tissue
Clinical samples from 10 normal individuals and 46 OSCC
patients were stained to confirm that GRP78 and HPA ex-
pression differed between these two groups. GRP78 was
expressed in the cytoplasm in all OSCC samples (Figure 1).
No GRP78 was expressed in any of the normal oral mucosa
samples. In this way, there was a significant difference in
the rate of expression of GRP78 between the OSCC group
and the control group (P = 0.003). Similarly, HPA-positive
expression signals were observed in 19 of 46 OSCC sam-
ples, but faint staining signals were observed in addition to
the more commonly observed cytoplasmic staining. HPA
was also found to localize in the nucleus and cytomem-
brane (Figure 1). There was a significant difference in the
rate of expression of HPA between the OSCC group and
the control group (P = 0.033).
Correlations between GRP78 expression in oral squamous
cell carcinoma and clinicopathological parameters
We observed a positive GRP78 expression in 27 of 46
OSCC samples (58.7%). The rate of GRP78 expression
was found to be closely related to tumor size (>3.1 cm,
P = 0.001), tumor stage (T3-T4, P = 0.001), lymphaticB-3
A-3
expressions in normal tissues and OSCC. (A) GRP78 expression in
tissues: no expression; A-2: GRP78 in OSCC tissues: negative expression;
C and normal tissues by immunostaining (c × 400). B-1: HPA in normal
PA in OSCC tissues: positive expression. GRP78, glucose-related protein
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P = 0.033), pathologic stage (III-IV, P = 0.000), and
histological grade (G3-G4, P = 0.018). However, the rate
of positive GRP78 expression showed no significant
correlation with gender, age, cigarette smoking, or al-
cohol consumption (Table 1).
Correlation between HPA expression in oral squamous
cell carcinoma and clinicopathological parameters
HPA expression was observed in 19 of 46 OSCC samples
(41.3%). The rate of HPA expression was found to be
closely related to tumor size (>3.1; P = 0.036), tumor stage
(T3 -T4; P = 0.000), lymphatic metastasis (N1-3; P = 0.012),
distant metastasis (M1; P = 0.000), pathologic stage (III-IV;
P = 0.000) and histological grade (G3-G4; P = 0.016). How-
ever, the rate of positive HPA expression showed no signifi-
cant correlation with gender, age, cigarette smoking status,
or alcohol consumption (Table 1).
Correlations between GRP78 and HPA expression
There was a significant positive correlation between the
expression of GRP78 and HPA (r = 0.435, P = 0.003) in
OSCC patients (Table 2).
Prognosis and multivariate analysis
The survival rate of patients who were positive for
GRP78 expression was significantly lower than that of
patients who were negative for GRP78 expression (Log-
rank Test, P = 0.002, Figure 2A). The survival rate of pa-
tients positive for HPA expression was significantly
lower than that of patients negative for HPA expression
(Log-rank Test, P = 0.000, Figure 2B). In addition, multi-
variate analysis showed age, distant metastasis, GRP78
expression, and HPA expression to be independent prog-
nostic factors of OSCC (P <0.05) (Table 3).
Discussion
Previous studies have shown that when the tumor micro-
environment becomes hypoxic, acidic, glucose-deprived, or
is subjected to radiation treatment, tumor cells can invade
and undergo metastasis. The same conditions can also in-
duce ERS. In the present study, correlations between HPA
expression and OSCC invasion and metastasis were ob-
served. Their possible implications in OSCC prognosis andTable 2 Correlations of GRP78 and HPA expression in OSCC





r,linear correlation; P <0.05 was considered to be statistically significant.survival were evaluated under ERS conditions. GRP78 is an
ER-stationed chaperone protein that has been characterized
on cell membranes and in the cytoplasm [5]. It is a central
regulator of ER function because of its roles in protein
folding and assembly, in the targeting of unfolded and mis-
folded proteins for degradation, ER Ca2+ binding, and con-
trol of the activation of transmembrane ERS sensors [6].
GRP78 is closely associated with ER stress-sensor proteins,
such as inositol-requiring enzyme, protein kinase-like ER
kinase, and activating transcription factor 6, but these sen-
sors have not yet been reported to be correlated with the
aggressiveness or progression of OSCC. For this reason, the
present study focused on the GRP78 expression, which was
believed to indicate the degree of ERS [13].
Previous studies have shown that a robust induction of
GRP78 takes place in many malignancies. This has been
described with respect to tumor progression and metas-
tasis. For example, a high level of GRP78 has been
shown to be more common in patients with high-grade
breast cancer than in healthy individuals [14]. A similar
pattern of expression was observed in lung cancer, pros-
tate cancer, hepatocellular carcinoma, colon cancer, and
gastric cancer [15-19]. The findings of the present study
on excised OSCC were consistent with those of previous
reports, and suggest that increased expression of GRP78
may be a feature of many malignant tumors found in
humans. Some papers have shown that the regulation
and expression of GRP78 are associated with shorter
overall survival [20-22]. The present study demonstrated
that positive GRP78 expression could also act as a pre-
dictor of shorter overall survival. Patients who were
positive for GRP78 expression showed a higher risk of
dying from OSCC than those with negative GRP78 ex-
pression. In this way, there is sufficient evidence to sup-
port the belief that GRP78 can serve as a marker of ERS,
and that it may play an important role in the develop-
ment and prognosis of OSCC.
The treatment of malignant tumors is a tough problem
in the field of clinical oncology. Tumor metastasis is the
cause of death of the majority of cancer patients. Previ-
ous studies have indicated that HPA expression is regu-
lated by P53, NF-KB, and ERS to promote invasion and
metastasis [23-25]. The present study focused on the re-
lationship between GRP78 and HPA. Thirty out of a
total of forty-six patients showed lymphatic metastasis
or distant metastasis, and 90% were positive for GRP78
expression. It can be hypothesized that, under ERS con-
ditions, HPA might be upregulated to help invasion and
metastasis. HPA upregulation has been documented in
many primary human tumors, such as bladder, gastric,
colorectal, and renal cancer [26-29]. The activation of
HPA enables tumor cells to break through the ECM and
BM. HPA releases several types of cytokines, including














Figure 2 Survival curves of the patients with OSCC. A: correlation between positive or negative GRP78 expression and prognostic implication
in OSCC patients. B: Correlation between HPA expression and prognostic implication in OSCC patients.
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crucial to promoting cell movement, enhancing tumor
cell invasion, and promoting tumor angiogenesis [30].
They are considered to be closely associated with inva-
sion, metastasis, and prognosis in multiple types of ma-
lignant tumors. Data collected in the present study
demonstrated that the expression of HPA in patientsTable 3 Cox regression analysis in overall survival of
OSCC patients
Risk factors RR 95% CI P
age 0.049 0. 007-0. 329 0. 002
Distant metastasis 7.566 1.243-46.049 0. 028
GRP78 0.023 0.002-0.239 0.002
HPA 0.08 0.001-0.110 0.000
95% CI, 95% confidence interval; RR, relative risk.with either lymphatic metastasis or distant metastasis
was higher than that in patients without metastasis, and
there was a significant positive correlation between the
expression of HPA and GRP78. In the present study, the
HPA protein was found to be highly expressed in most
advanced-stage OSCC tissues, and the proteins were
mainly located within the cytoplasm and nucleus. These
findings were consistent with those of a previously pub-
lished study [31]. In a separate study Jiang et al. showed
that knockdown of GRP78 can enhance the sensitivity of
melanoma to chemotherapy drugs [32]. In this way, it
can be hypothesized that removing the tumor protection
provided by ERS can reduce the level of HPA and en-
hance the sensitivity of chemotherapy drugs. This may
be one viable means of treating OSCC. However, the
clinical significance of GRP78 and HPA in OSCC has
not been fully explored thus far. A larger group of
Xia et al. World Journal of Surgical Oncology 2014, 12:121 Page 7 of 8
http://www.wjso.com/content/12/1/121patients with long-term follow up is needed and more
cellular experiments should be performed to confirm
this conclusion.
Conclusions
The current study is the first to explain the progression,
metastasis, and prognosis of oral cancer progression
from the perspective of ERS. HPA expression was found
to be positively correlated with ERS. GRP78 and HPA
are biomarkers that may have the potential to guide the
treatment of oral cancer patients.
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